こはく酸メトプロロール

プロパティ

安全情報

説明

Metoprolol succinate represents an entirely novel extended-release formulation of metoprolol, requiring administration only once daily to ensure constant metoprolol blood concentrations and sustained β1-adrenergic blocking effects throughout the 24-hour period. It offers numerous advantages in both pharmacology and clinical therapeutics. Clinically, it is primarily indicated for the management of hypertension,High blood pressure medication,angina pectoris, and stable chronic heart failure with left ventricular systolic dysfunction.
Administer orally once daily, preferably in the morning. Tablets may be divided but must not be chewed or crushed. Swallow with at least half a glass of liquid. Concomitant food intake does not affect bioavailability. Dosage should be individualised to avoid bradycardia. Effective dosing guidelines are as follows: Hypertension: 47.5–95 mg once daily. Patients unresponsive to 95 mg metoprolol succinate sustained-release tablets may combine with other antihypertensives, preferably diuretics and dihydropyridine calcium channel blockers, or increase dosage. Angina pectoris: 95–190 mg once daily. May be combined with nitrates or increased dosage as required.